The cardiovascular link to nonalcoholic fatty liver disease: A critical analysis

Clinics in Liver Disease

Volumn 16, Issue 3, 2012, Pages 599-613

  Pacana, Tommy ^a   Fuchs, Michael ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular disease; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Subclinical atherosclerosis

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; GAMMA GLUTAMYLTRANSFERASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; SCAVENGER RECEPTOR BI;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTERIAL WALL THICKNESS; ARTERY BLOOD FLOW; ATHEROGENIC DIET; ATHEROSCLEROSIS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CHRONICITY; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY CALCIFICATION; DISEASE CLASSIFICATION; DISEASE COURSE; DYSLIPIDEMIA; ECHOGRAPHY; FOLLOW UP; FRAMINGHAM RISK SCORE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEPATITIS C; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; LIPOPROTEIN METABOLISM; LIVER BIOPSY; MASS SCREENING; METABOLIC SYNDROME X; MORTALITY; NONALCOHOLIC FATTY LIVER; PULSE WAVE; REVIEW; RISK FACTOR; UPREGULATION; VASODILATATION;

BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; DISEASE PROGRESSION; DYSLIPIDEMIAS; FATTY LIVER; FEMALE; HUMANS; INSULIN RESISTANCE; LIPOPROTEINS, HDL; LIVER; LIVER CIRRHOSIS; MALE; METABOLIC SYNDROME X; VASODILATION;

EID: 84864088930     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2012.05.008     Document Type: Review

References (83)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002, 346:1221-1231.
2. Farrell G.C., Larter C.Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology 2006, 43:S99-S112.
3. Lazo M., Clark J.M. The epidemiology of nonalcoholic fatty liver disease: a global perspective. Semin Liver Dis 2008, 28:339-350.
4. Clark J.M., Diehl A.M. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003, 289:3000-3004.
5. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003, 37:1202-1219.
6. Browning J.D., Szczepaniak L.S., Dobbins R., et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004, 40:1387-1395.
7. Edmison J., McCullough A.J. Pathogenesis of non-alcoholic steatohepatitis: human data. Clin Liver Dis 2007, 11:75-104.
8. Clark J.M. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006, 40(Suppl 1):S5-S10.
9. Dunn W., Schwimmer J.B. The obesity epidemic and nonalcoholic fatty liver disease in children. Curr Gastroenterol Rep 2008, 10:67-72.
10. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
11. Kotronen A., Yki-Järvinen H. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 2008, 28:27-38.
12. Marchesini G., Bugianesi E., Forlani G., et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003, 37:917-923.
13. Marchesini G., Marzocchi R., Agostini F., et al. Nonalcoholic fatty liver disease and the metabolic syndrome. Curr Opin Lipidol 2005, 16:421-427.
14. Mensah G.A., Mokdad A.H., Ford E., et al. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol Clin 2004, 22:485-504.
15. Yusuf S., Hawken S., Ounpuu S., et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364:937-952.
16. Lorenzo C., Williams K., Hunt K.J., et al. The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes. Diabetes Care 2007, 30:8-13.
17. Mottillo S., Filion K.B., Genest J., et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010, 56:1113-1132.
18. Targher G., Day C.P., Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010, 363:1341-1350.
19. Targher G., Bertolini L., Padovani R., et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 2007, 30:1212-1218.
20. Targher G., Bertolini L., Padovani R., et al. Prevalence of non-alcoholic fatty liver disease and its association with cardiovascular disease in patients with type 1 diabetes. J Hepatol 2010, 53:713-718.
21. Picardi A., Vespasiani-Gentilucci U. Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass. Am J Gastroenterol 2008, 103:3036-3038.
22. Ong J.P., Pitts A., Younossi Z.M. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008, 49:608-612.
23. Dunn W., Xu R., Wingard D.L., et al. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study. Am J Gastroenterol 2008, 103:2263-2271.
24. Ekstedt M., Franzén L.E., Mathiesen U.L., et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006, 44:865-873.
25. Söderberg C., Stål P., Askling J., et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010, 51:595-602.
26. Rafiq N., Bai C., Fang Y., et al. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009, 7:234-238.
27. Lazo M., Hernaez R., Bonekamp S., et al. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ 2011, 343:d6891.
28. Simon A., Chironi G., Levenson J. Comparative performance of subclinical atherosclerosis tests in predicting coronary heart disease in asymptomatic individuals. Eur Heart J 2007, 28:2967-2971.
29. Lorenz M.W., Markus H.S., Bots M.L., et al. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 2007, 115:459-467.
30. Cao J.J., Arnold A.M., Manolio T.A., et al. Association of carotid artery intima-media thickness, plaques, and C-reactive protein with future cardiovascular disease and all-cause mortality: the Cardiovascular Health study. Circulation 2007, 116:32-38.
31. Simon A., Megnien J.L., Chironi G. The value of carotid intima-media thickness for predicting cardiovascular risk. Arterioscler Thromb Vasc Biol 2010, 30:182-185.
32. McKimmie R.L., Daniel K.R., Carr J.J., et al. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. Am J Gastroenterol 2008, 103:3029-3035.
33. Manco M., Bedogni G., Monti L., et al. Intima-media thickness and liver histology in obese children and adolescents with non-alcoholic fatty liver disease. Atherosclerosis 2010, 209:463-468.
34. Targher G., Bertolini L., Padovani R., et al. Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease. Diabetes Care 2006, 29:1325-1330.
35. Sookoian S., Pirola C.J. Non-alcoholic fatty liver disease is strongly associated with carotid atherosclerosis: a systematic review. J Hepatol 2008, 49:600-607.
36. Johnsen S.H., Mathiesen E.B., Joakimsen O., et al. Carotid atherosclerosis is a stronger predictor of myocardial infarction in women than in men: a 6-year follow-up study of 6226 persons: the Tromsø study. Stroke 2007, 38:2873-2880.
37. Plichart M., Celermajer D.S., Zureik M., et al. Carotid intima-media thickness in plaque-free site, carotid plaques and coronary heart disease risk prediction in older adults. The Three-City study. Atherosclerosis 2011, 219:917-924.
38. Jain A., McClelland R.L., Polak J.F., et al. Cardiovascular imaging for assessing cardiovascular risk in asymptomatic men versus women: the multi-ethnic study of atherosclerosis (MESA). Circ Cardiovasc Imaging 2011, 4:8-15.
39. Chen C.H., Nien C.K., Yang C.C., et al. Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci 2010, 55:1752-1760.
40. Assy N., Djibre A., Farah R., et al. Presence of coronary plaques in patients with nonalcoholic fatty liver disease. Radiology 2010, 254:393-400.
41. Jung D.H., Lee Y.J., Ahn H.Y., et al. Relationship of hepatic steatosis and alanine aminotransferase with coronary calcification. Clin Chem Lab Med 2010, 48:1829-1834.
42. Arad Y., Goodman K.J., Roth M., et al. Coronary calcification, coronary disease risk factors, C-reactive protein, and atherosclerotic cardiovascular disease events: the St. Francis Heart study. J Am Coll Cardiol 2005, 46:158-165.
43. Villanova N., Moscatiello S., Ramilli S., et al. Endothelial dysfunction and cardiovascular risk profile in nonalcoholic fatty liver disease. Hepatology 2005, 42:473-480.
44. Yeboah J., Folsom A.R., Burke G.L., et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009, 120:502-509.
45. Laurent S., Cockcroft J., Van Bortel L., et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006, 27:2588-2605.
46. Mattace-Raso F.U., van der Cammen T.J., Hofman A., et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam study. Circulation 2006, 113:657-663.
47. Sutton-Tyrrell K., Najjar S.S., Boudreau R.M., et al. Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005, 111:3384-3390.
48. Salvi P., Ruffini R., Agnoletti D., et al. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hypertens 2010, 28:1699-1707.
49. Vlachopoulos C., Manesis E., Baou K., et al. Increased arterial stiffness and impaired endothelial function in nonalcoholic Fatty liver disease: a pilot study. Am J Hypertens 2010, 23:1183-1189.
50. Ruttmann E., Brant L.J., Concin H., et al. Gamma-glutamyl transferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation 2005, 112:2130-2137.
51. Strasak A.M., Kelleher C.C., Klenk J., et al. Longitudinal change in serum gamma-glutamyl transferase and cardiovascular disease mortality: a prospective population-based study in 76,113 Austrian adults. Arterioscler Thromb Vasc Biol 2008, 28:1857-1865.
52. Fraser A., Harris R., Sattar N., et al. Gamma-glutamyl transferase is associated with incident vascular events independently of alcohol intake: analysis of the British Women's Heart and Health Study and Meta-Analysis. Arterioscler Thromb Vasc Biol 2007, 27:2729-2735.
53. Wannamethee S.G., Lennon L., Shaper A.G. The value of gamma-glutamyl transferase in cardiovascular risk prediction in men without diagnosed cardiovascular disease or diabetes. Atherosclerosis 2008, 201:168-175.
54. Schindhelm R.K., Dekker J.M., Nijpels G., et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn study. Atherosclerosis 2007, 191:391-396.
55. Ioannou G.N., Weiss N.S., Boyko E.J., et al. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006, 43:1145-1151.
56. Goessling W., Massaro J.M., Vasan R.S., et al. Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology 2008, 135:1935-1944.
57. Olynyk J.K., Knuiman M.W., Divitini M.L., et al. Serum alanine aminotransferase, metabolic syndrome, and cardiovascular disease in an Australian population. Am J Gastroenterol 2009, 104:1715-1722.
58. Emdin M., Pompella A., Paolicchi A. Gamma-glutamyl transferase, atherosclerosis, and cardiovascular disease: triggering oxidative stress within the plaque. Circulation 2005, 112:2078-2080.
59. Targher G., Bertolini L., Poli F., et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. Diabetes 2005, 54:3541-3546.
60. Targher G., Bertolini L., Rodella S., et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabetes Care 2007, 30:2119-2121.
61. Hamaguchi M., Kojima T., Takeda N., et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. World J Gastroenterol 2007, 13:1579-1584.
62. Haring R., Wallaschofski H., Nauck M., et al. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels. Hepatology 2009, 50:1403-1411.
63. Saadeh S., Younossi Z.M., Remer E.M., et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002, 123:745-750.
64. Adams L.A., Lymp J.F., St Sauver J., et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005, 129:113-121.
65. Sanyal A.J., Banas C., Sargeant C., et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006, 43:682-689.
66. Fuchs M., Sanyal A.J. Non-alcoholic fatty liver disease: a pathophysiological perspective. The liver: biology and pathobiology 2009, 719-741. John Wiley & Sons, Chichester (UK). 5th edition. I.M. Arias, H.J. Alter, J.L. Boyer (Eds.).
67. Ridker P.M., Rifai N., Rose L., et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
68. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003, 108:2317-2322.
69. Thögersen A.M., Jansson J.H., Boman K., et al. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 1998, 98:2241-2247.
70. Adiels M., Taskinen M.R., Borén J. Fatty liver, insulin resistance, and dyslipidemia. Curr Diab Rep 2008, 8:60-64.
71. Bamba V., Rader D.J. Obesity and atherogenic dyslipidemia. Gastroenterology 2007, 132:2181-2190.
72. Khera A.V., Cuchel M., de la Llera-Moya M., et al. Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med 2011, 364:127-135.
73. Sanyal A.J., Mudaliar S., Henry R.R., et al. A new therapy for nonalcoholic fatty liver disease and diabetes? INT-747-the first FXR hepatic therapeutic study. Hepatology 2009, 50:389A.
74. Claudel T., Sturm E., Duez H., et al. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 2002, 109:961-971.
75. Evans M.J., Mahaney P.E., Borges-Marcucci L., et al. A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia. Am J Physiol Gastrointest Liver Physiol 2009, 296:G543-G552.
76. Shah P.K. Screening asymptomatic subjects for subclinical atherosclerosis: can we, does it matter, and should we?. J Am Coll Cardiol 2010, 56:98-105.
77. Greenland P., Alpert J.S., Beller G.A., et al. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010, 56:e50-e103.
78. Lee Y.H., Wu Y.J., Liu C.C., et al. The severity of Fatty liver disease relating to metabolic abnormalities independently predicts coronary calcification. Radiol Res Pract 2011, 2011:8. Article ID 586785. 10.1155/2011/586785.
79. Folsom A.R., Kronmal R.A., Detrano R.C., et al. Coronary artery calcification compared with carotid intima-media thickness in the prediction of cardiovascular disease incidence: the Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med 2008, 168:1333-1339.
80. Danesh J., Wheeler J.G., Hirschfield G.M., et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004, 350:1387-1397.
81. Yoneda M., Mawatari H., Fujita K., et al. High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH. J Gastroenterol 2007, 42:573-582.
82. Lee D.S., Evans J.C., Robins S.J., et al. Gamma glutamyl transferase and metabolic syndrome, cardiovascular disease, and mortality risk: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2007, 27:127-133. [Epub 2006 Nov 9].
83. Adams L.A., Angulo P. Treatment of non-alcoholic fatty liver disease. Postgrad Med J 2006, 82:315-322.